GSK Reports Q1 2023 Revenue of £7 Billion, Up 10% Excluding COVID-19 Products

According to a message published on GSK China's WeChat Official Account on April 27, GSK's Q1 financial report shows that the total revenue was £7 billion, an 8% decrease. Excluding the COVID-19 solutions, it increased by 10%. Among this, the vaccine business was £2 billion, the specialty medicine business was £2.2 billion, and the general medicine business was £2.7 billion.